22nd Century Featured on the Cover of Tobacco International Magazine
April 25 2016 - 10:13AM
Business Wire
Company’s Disruptive Technology is the
Foundation of its Harm Reduction Strategy
22nd Century Group, Inc. (NYSE MKT: XXII),
a plant biotechnology company that is a leader in tobacco harm
reduction, announced today that 22nd Century is the featured cover
story of the newest issue of Tobacco International magazine (see
www.tobaccointernational.com). In a feature story entitled, “The
Turn of the XXII Century Group,” Murdoch McBride, Editor-in Chief
of Tobacco International, interviews 22nd Century Group Chief
Executive Officer, Henry Sicignano III, to explore the Company’s
technology, ambitions, and important mission.
In the cover article, McBride remarks: “Under CEO Henry
Sicignano III, we are now seeing something of a turn of the
century, with XXII transitioning from an early R&D [only] focus
to the commercialization of its proprietary technology…” 22nd
Century remains, at its core, an innovative biotechnology company
that is aggressively pursuing the application of its game-changing
technology to reduce the harm caused by smoking. McBride calls this
disruptive mission a “bold endeavor” and then poses probing
questions throughout the interview, both to understand the spirited
biotechnology company and to determine what the future may hold for
22nd Century’s remarkable technology.
When asked about 22nd Century’s near term and longer term goals,
Sicignano sums up the Company’s activities succinctly:
“1. Secure an FDA marketing order for BRAND
A, Very Low Nicotine reduced exposure cigarettes in the United
States; 2. Announce a strategic partner for Phase III clinical
trials in support of X-22, the Company’s smoking cessation product;
and 3. Grow sales and profits for 22nd Century. Well within the
next five years, the Company also plans to 1. Launch BRAND A in the
United States; 2. Submit a Modified Risk Tobacco Product
application to the FDA for BRAND B, low tar-to-nicotine ratio
cigarettes; 3. Apply for FDA approval for X-22… and launch X-22 in
the United States; and 4. Introduce 22nd Century’s proprietary
tobacco products in Asia. Achieving any one or more of these
important goals will transform 22nd Century into a true industry
leader as it helps millions of people around the world reduce the
harm caused by smoking.”
Later in the interview, McBride moves the discussion from
tobacco science to cannabis technology, noting that “though
cannabis is outside Tobacco International’s purview, 22nd Century
holds the exclusive license in the U.S. for the technology to
increase or decrease levels of cannabinoids in the cannabis plant.”
On this topic, McBride asks, “[Has] the cannabis genome been fully
mapped and how important an area of interest [is] cannabis… for
XXII?”
Sicignano responds: “The cannabis genome is sequenced, though
the sequencing does appear to have gaps…. [22nd Century] intends to
be the world leader in cannabis research through its ongoing
research partnership with Anandia Laboratories in Canada.”
Sicignano adds: “Dr. [Paul] Rushton [the Company’s Vice President
of Plant Biotechnology] will work to ensure that 22nd Century is
one of the world’s foremost leaders in sponsored research on the
cannabis plant with the objectives of producing low/no THC strains
for use in hemp production and high CBD strains for use in the
medical marijuana markets.”
McBride concludes the interview by asking Sicignano about the
many regulatory hurdles faced by 22nd Century. In answering this
question, Sicignano again asserts 22nd Century’s determination to
achieve the Company’s important harm reduction mission: “While
successfully navigating regulatory issues does impact 22nd Century
greatly, the Company is not simply following the path of least
resistance… Instead, 22nd Century seeks to introduce its products
[and technology] where they will accomplish the most good…”
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on
technology which allows it to increase or decrease the level of
nicotine in tobacco plants and the level of cannabinoids in
cannabis plants through genetic engineering and plant breeding. The
Company’s primary mission is to reduce the harm caused by smoking.
22nd Century currently owns or exclusively controls more than 200
issued patents and more than 50 pending patent applications around
the world. The Company’s strong IP position led to a licensing
agreement with British American Tobacco (“BAT”), the world’s second
largest tobacco company. Visit www.xxiicentury.com,
www.magiccigarettes.com, or www.redsuncigarettes.com for more
information.
About Tobacco International
Founded in 1886, Tobacco International is the tobacco industry’s
leading trade journal for tobacco product manufacturers and the
leaf trade. It provides readers with the cutting-edge
tobacco-related news coverage and reaches more than 11,000
subscribers (the most of any tobacco industry publication),
including top-level industry members worldwide. Visit
www.tobaccointernational.com for more information.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release, including but not limited to our future revenue
expectations. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2015, filed on February 18, 2016,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S. Securities and Exchange Commission
which attempt to advise interested parties of the risks and factors
that may affect our business, financial condition, results of
operation and cash flows. If one or more of these risks or
uncertainties materialize, or if the underlying assumptions prove
incorrect, our actual results may vary materially from those
expected or projected.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160425005939/en/
Investor Relations:IRTH CommunicationsAndrew Haag,
866-976-4784xxii@irthcommunications.comorRedington, Inc.Tom
Redington, 203-222-7399
22nd Century (AMEX:XXII)
Historical Stock Chart
From Mar 2024 to Apr 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From Apr 2023 to Apr 2024